Viral Vector Vaccine

A viral vector vaccine is an immunisation platform that employs a genetically engineered, replication-deficient or attenuated virus—the vector—to transport DNA encoding an antigen from a target pathogen into human cells, where the host's own machinery transcribes and translates that gene to manufacture the antigen and provoke an adaptive immune response. The conceptual foundation rests on recombinant DNA technology developed from the 1970s onward and on adenovirus and poxvirus biology characterised through the 1980s and 1990s. Regulatory architecture in India governs such products through the Drugs and Cosmetics Act, 1940, the New Drugs and Clinical Trials Rules, 2019, and the oversight of the Central Drugs Standard Control Organisation (CDSCO) together with the Department of Biotechnology's Review Committee on Genetic Manipulation (RCGM) and Genetic Engineering Appraisal Committee (GEAC), since the platform involves living genetically modified organisms. Globally, the World Health Organization's prequalification and Emergency Use Listing mechanisms, alongside the US FDA and the European Medicines Agency, supply the licensing framework.

The procedural mechanics begin with selecting a carrier virus—commonly an adenovirus—and deleting genes essential for its replication, typically the E1 and E3 regions, rendering it incapable of multiplying in the recipient while preserving its ability to infect cells once. Scientists then splice into the vector's genome the gene coding for the target antigen, such as the SARS-CoV-2 spike glycoprotein. After the engineered vector is grown in permissive producer cell lines, purified and formulated, it is administered intramuscularly. The vector enters host cells, releases its genetic payload into the nucleus where the antigen gene is transcribed, and the cell expresses the foreign antigen on or near its surface. The immune system recognises this antigen as alien, mounting both humoral responses through neutralising antibodies and cellular responses via cytotoxic T lymphocytes, thereby establishing immunological memory.

Two principal variants exist. Non-replicating vectors, the more widely used class, cannot reproduce inside the body after the initial infection, limiting antigen production to the initially transduced cells and prioritising safety. Replicating vectors, often attenuated, can produce further viral copies that infect additional cells, generating a stronger and more sustained antigenic stimulus, as exemplified by the vesicular stomatitis virus backbone in certain Ebola vaccines. A recurring design challenge is anti-vector immunity: pre-existing antibodies against common human adenoviruses, particularly serotype 5, can neutralise the vector before it delivers its cargo. Developers counter this by using rare human serotypes, chimpanzee adenoviruses to which human populations are naïve, or heterologous prime-boost regimens that deploy two different vectors in successive doses.

Named contemporary instances anchor the concept. The Oxford–AstraZeneca vaccine (ChAdOx1 nCoV-19), manufactured in Pune by the Serum Institute of India as Covishield, used a chimpanzee adenovirus vector and received CDSCO restricted emergency-use approval in January 2021, becoming the backbone of India's COVID-19 programme. Russia's Gamaleya Institute developed Sputnik V, a heterologous platform pairing adenovirus-26 for the prime and adenovirus-5 for the boost, approved in Russia in August 2020 and granted emergency use in India in April 2021. Johnson & Johnson's Janssen vaccine relied on an Ad26 vector. Earlier, Merck's Ervebo, an rVSV-ZEBOV replicating vector vaccine against Ebola, was deployed during the 2018–2020 outbreaks in the Democratic Republic of the Congo and received WHO prequalification in 2019.

The platform must be distinguished from adjacent technologies. Unlike an mRNA vaccine—such as the Pfizer-BioNTech or Moderna products—which delivers naked messenger RNA encapsulated in lipid nanoparticles and requires ultra-cold storage, the viral vector platform packages DNA inside a protein viral coat that confers greater thermal stability, allowing storage at standard refrigeration temperatures of 2–8°C, a decisive advantage for cold-chain-constrained settings. It differs from inactivated vaccines like Bharat Biotech's Covaxin, which present a whole killed pathogen, and from subunit and protein-based vaccines that inject the manufactured antigen directly rather than the genetic instructions to make it. The shared feature with mRNA platforms is that both instruct host cells to synthesise the antigen, in contrast to introducing the antigen externally.

Edge cases and controversies attend the platform. Rare thrombotic events with thrombocytopenia syndrome (TTS), an immune reaction producing blood clots with low platelet counts, were associated with adenovirus-vectored COVID-19 vaccines, prompting several European states to restrict the AstraZeneca product by age group in 2021 and leading AstraZeneca to withdraw the vaccine from the market in 2024 citing commercial reasons. Anti-vector immunity also complicates booster strategies, since repeated use of the same vector diminishes efficacy. Theoretical concerns about insertional mutagenesis, though the adenoviral DNA remains episomal and does not integrate into the host genome, continue to inform regulatory scrutiny under biosafety guidelines.

For the working practitioner—whether a civil-services aspirant addressing GS Paper 3 science-and-technology questions, a health-ministry desk officer, or a diplomat negotiating vaccine procurement—the viral vector vaccine illustrates the intersection of biotechnology, public-health security and international cooperation. India's manufacturing of Covishield underpinned the Vaccine Maitri initiative through which New Delhi supplied doses to neighbouring and developing states, demonstrating vaccine diplomacy as an instrument of soft power. Understanding the platform's cold-chain resilience, regulatory pathway and comparative trade-offs against mRNA technology is essential for assessing pandemic preparedness, the COVAX equity framework, and debates over technology transfer and TRIPS waivers at the World Trade Organization.